13
1
1
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T30161 | EN3356 | AS N001,ASN-001 | P450 |
EN3356 is an orally available and selective inhibitor of steroidal 17-alpha-hydroxylase/C17,20 cleavage enzyme (CYP17A1 or CYP17), a non-steroidal cleavage enzyme-selective compound with potential anti-androgenic and ant... | |||
T6215 | Abiraterone Acetate | Zytiga,CB7630 | P450 |
Abiraterone Acetate (CB7630) is an androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER. | |||
T6509 | Galeterone | VN-124-1,TOK-001,VN/124-1,VN 124 | P450 , Androgen Receptor |
Galeterone (VN 124) is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an a... | |||
T6216 | Abiraterone | CB-7598 | P450 |
Abiraterone (CB-7598) (CB-7598) is an effective steroidal cytochrome P450 17alpha-hydroxylase-17, 20-lyase (CYP17) inhibitor (IC50: 4 nM). | |||
T12289 | ODM-204 | Others | |
ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme(IC50s of 80 nM and 22 nM, respectively). | |||
T13525 | Abiraterone metabolite 1 | 3β-OH-5α-Abi | Others |
Abiraterone Metabolite 1, a 5β-reduced derivative of abiraterone, acts by inhibiting CYP17A1, thereby blocking androgen synthesis and extending survival in prostate cancer patients. | |||
T10946 | D4-abiraterone | Abiraterone D4A metabolite,CB-7627,Δ4-Abiraterone | Androgen Receptor |
D4-Abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid 5a-reductase (SRD5A), the main metabolite of abiraterone. D4-Abiraterone is also an antagonist of androgen receptor. | |||
T71102 | CFG920 | ||
CFG920 is a CYP17 inhibitor, is also an orally available inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration,... | |||
T74684 | Abiraterone sulfate | ||
Abiraterone sulfate is a metabolite of Abiraterone . Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity [1] . | |||
T74685 | Abiraterone N-oxide | ||
Abiraterone N-oxide is a metabolite of Abiraterone . Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity [1] . | |||
T79519 | YXG-158 | Androgen Receptor | |
YXG-158 (Compound 23-h), an orally active androgen receptor (AR) degrader and cytochrome P450 17A1 (CYP17A1) inhibitor, exhibits AR degradation with a DC50 of 1.28 μM and CYP17A1 inhibition with an IC50 of 100 nM. It is ... | |||
T74094 | 5,6-Dihydroabiraterone | ||
5,6-Dihydroabiraterone, a metabolic derivative of Abiraterone, is a potent and irreversible inhibitor of CYP17A1, exhibiting antiandrogen and antitumor activities, particularly effective against castration-resistant pros... | |||
T70847 | BMS-351 | ||
BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely t... |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T0603 | Phthalic acid mono-2-ethylhexyl ester | Phthalic Acid Monooctyl Ester | P450 , Endogenous Metabolite |
Phthalic acid mono-2-ethylhexyl ester (Phthalic Acid Monooctyl Ester is a major bioactive metabolite of diethylhexyl phthalate (DEHP), which inhibits the 17, 20 lyase activity of CYP17. Cyp17a1 gene is a specific target ... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-02139 | CYP17A1 Protein, Human, Recombinant (GST) | Human | E. coli |
A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis. Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen sy... |